AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 22 - (NewsRx.com & NewsRx.net) -- The National Institute of Health "Women's Health Initiative," a large-scale study examining the long-term health benefits of hormone replacement therapy (HRT) in healthy women which was halted due to overall health risks to study participants, only examined one oral product, Prempro.
The long-term health risks identified by the study apply to oral therapies with the same ingredients and doses - they were not established for transdermal HRT or HRT utilizing different forms of estrogens and progestogens.
"The results of the Women's Health Initiative (WHI) are understandably worrisome for both physicians and women using HRT long-term," said Fran Dapas, MD, director of medical affairs at Novogyne Pharmaceuticals. "However, when re-evaluating therapy plans, it is important to keep in mind that transdermal HRT is different from oral forms. By delivering the drugs straight through the skin and directly into the blood stream, transdermal HRT avoids first-pass liver metabolism, resulting in a consistent rate of delivery similar to release from the ovaries."
CombiPatch contains estradiol and the progestogen, norethindrone acetate (NETA), both derived from plants, whereas the study drug, ...
Source: HighBeam Research, Patch Manufacturer: Don't extrapolate HRT study results to patches.